Design, Synthesis and Anticonvulsant Activity Evaluation of Novel 4-(4-Substitutedphenyl)-3-Methyl-1H-1,2,4-Triazol-5(4H)-Ones

 

 Buy Article Permissions and Reprints

Abstract

A series of novel 4-(4-substitutedphenyl)-3-methyl-1H-1,2,4-triazol-5(4H)-one derivatives were synthesized and screened for their anticonvulsant activities by the maximal electroshock test (MES) and their neurotoxicity was evaluated by the rotarod neurotoxicity test (TOX). In the MES test, compound 4-{4-[(3-fluorobenzyl)oxy]phenyl}-3-methyl-1H-1,2,4-triazol-5(4H)-one (4n) was found to possess better anticonvulsant activity and higher safety than marketed drugs Carbamazepine with an ED₅₀ value of 25.5 mg/kg and protective index (PI) value>48.8. In addition, the potency of compound 4n against seizures induced by Pentylenetetrazole, 3-Mercaptopropionic acid, and Bicuculline suggested its broad spectrum activity, and the mechanisms of action including inhibition of voltage-gated ion channels and modulation of GABAergic activity might involve in its anticonvulsant activity.

• References

• 1 Strine TW, Kobau R, Chapman DP et al. Psychological distress, comorbidities, and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia. 2005 46. 1133-1139
  PubMedGoogle Scholar
• 2 Mc Namara OJ, Brunton LL, Lazo JS, et al. eds. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006: 501-526
• 3 Husain A, Rashid M, Akhter A et al. Design, synthesis and pharmacological activities of novel N-1-2-(substituted phenyl)-4-oxo-1,3-thiazolan-3-yl-2,2-diphenyl-acetamides. Int J Pharm Sci Rev Res 2010; 5: 102-106
  PubMedGoogle Scholar
• 4 Stefan H, Feuerstein T. Novel anticonvulsant drugs. Pharmacol Ther 2007; 113: 165-183
  CrossrefPubMedGoogle Scholar
• 5 Donner EJ, Snead OC. New generation anticonvulsants for the treatment of epilepsy in children. NeuroRX 2006; 3: 170-180
  CrossrefPubMedGoogle Scholar
• 6 Bootsma HP, Ricker L, Hekster YA et al. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure 2009; 18: 327-331
  CrossrefPubMedGoogle Scholar
• 7 Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. CNS Drugs 2008; 22: 739-760
  CrossrefPubMedGoogle Scholar
• 8 Penovich PE, James Willmore L. Use of a new antiepileptic drug or an old one as first drug for treatment of absence epilepsy. Epilepsia 2009; 50: 37-41
  PubMedGoogle Scholar
• 9 Bialer M, Johannessen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 2007; 73: 1-52
  CrossrefPubMedGoogle Scholar
• 10 Bialer M, Yagen B. Valproic acid: second generation. Neurotherapeutics 2007; 4: 130-137
  CrossrefPubMedGoogle Scholar
• 11 Husain A, Rashid M, Akhter A et al. Synthesis of new 1,2,4-triazolo3,4-B[1,3,4]thiadiazole derivatives and their pharmacological evaluation. J Pharm Res 2011; 4: 888-890
  PubMedGoogle Scholar
• 12 Unverferth K, Engel J, Hofgen N et al. Synthesis, Anticonvulsant Activity, and Structure-Activity Relationships of Sodium Channel Blocking 3-Aminopyrroles. J Med Chem 1998; 41: 63-73
  CrossrefPubMedGoogle Scholar
• 13 Kaushik D, Khan SA, Chawla G. Design and synthesis of 2-(substituted aryloxy)-5-(substituted benzylidene)-3-phenyl-2,5-dihydro-1H-[1,2,4] triazin-6-one as potential anticonvulsant agents. Eur J Med Chem 2010; 45: 3960-3969
  CrossrefPubMedGoogle Scholar
• 14 Hassan MZ, Khan SA, Amir M. Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl)amides as anticonvulsant and neuroprotective. Eur J Med Chem 2012; 58: 206-213
  CrossrefPubMedGoogle Scholar
• 15 Kaushik D, Khan SA, Chawla G et al. N’-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-methylene] 2,4-substituted hydrazides: Synthesis and anticonvulsant activity. Eur J Med Chem. 2010 45. 3943-3949
  PubMedGoogle Scholar
• 16 Siddiqui N, Ahsan W. Triazole incorporated thiazoles as a new class of anticonvulsants: Design, synthesis and in vivo screening. Eur J Med Chem 2010; 45: 1536-1543
  CrossrefPubMedGoogle Scholar
• 17 Siddiqui N, Alam MS, Stables JP. Synthesis and anticonvulsant properties of 1-(amino-N-arylmethanethio)-3-(1-substitutedbenzyl-2,3-dioxo­indolin-5-yl) urea derivatives. Eur J Med Chem 2011; 46: 2236-2242
  CrossrefPubMedGoogle Scholar
• 18 Jin HG, Sun XY, Chai KY et al. Anticonvulsant and toxicity evaluation of some 7-alkoxy-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline-1(2H)-ones. Bioorg Med Chem 2006; 14: 6868-6873
  CrossrefPubMedGoogle Scholar
• 19 Krall RJ, Penry JK, White BG et al. Antiepileptic drug development: II Anticovulsant drug screening. Epilepsia. 1978. 19. 409-428
  Google Scholar
• 20 Poter RJ, Cereghino JJ, Gladding GD et al. Antiepileptic drug development program. Cleve Clin 1984; 51: 293-305
  PubMedGoogle Scholar
• 21 Arnoldi A, Bonsignori A, Melloni P et al. Synthesis and anticonvulsant and sedative-hypnotic activity of 4-(alkylimino)-2,3-dihydro-4H-1-ben-zopyrans and -benzothiopyrans. J Med Chem 1990; 33: 2865-2869
  CrossrefPubMedGoogle Scholar
• 22 Löscher W, Schmidt D. A proposal based on experimental and clinical considerations. Epilepsy Res 1988; 2: 145-181
  CrossrefPubMedGoogle Scholar
• 23 White HS. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 2003; 44: 2-8
  PubMedGoogle Scholar
• 24 Levy RH, Mattson RH, Meldrum BS. eds. General principles: experimental selection, quantification, and evaluation of antiepileptic drugs. New York: Raven Press; 1995: 99-110
• 25 Waterbeemed HV. The Practice of Medicinal Chemistry. London: Academic Press; 1996. 367.
  Google Scholar
• 26 Okada R, Negishi N, Nagaya H. The role of the nigrotegmental GABAergic pathway in the propagation of pentylenetetrazol-induced seizures. Brain Res 1989; 480: 383-387
  CrossrefPubMedGoogle Scholar
• 27 Olsen RW. GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 1981; 37: 1-13
  CrossrefPubMedGoogle Scholar
• 28 Gale K. Basic concepts from preclinical research. Epilepsia 1992; 33: S3-S12
  CrossrefPubMedGoogle Scholar
• 29 Löscher W. 3-Mercaptopropionic acid: Convulsant properties, effects on enzymes of the γ-aminobutyrate system in mouse brain and antagonism by certain anticonvulsant drugs, aminooxyacetic acid and gabaculine. Biochem Pharmacol 1979; 28: 1397-1407
  CrossrefPubMedGoogle Scholar
• 30 Macdonald RL, Barker JL. Specific antagonism of GABA-mediated postsynaptic inhibition in cultured spinal cord neurons: a common mode of convulsant action. Neurology 1978; 28: 325-330
  CrossrefPubMedGoogle Scholar